Together we make progress

EPROPA (European Program for ROutine testing of Patients with Advanced lung cancer) is a program addressed to European patients with oncogene-addicted advanced Non Small Cell Lung Cancer (NSCLC) to increase the opportunities of molecular diagnostics and facilitate the access to clinical trials.

A European network dedicated to connecting patients

 

To increase their molecular screening

The advent of Next-Generation Sequencing in the management of NSCLC patients had improved their therapeutic opportunities.

 

To facilitate their accrual in clinical trials

Defining the molecular landscape of these patients allows to identify alterations actionable by targeted therapies.

 

To provide them a logistic support

To match this information with the accessibility into clinical trials is of paramount relevance toward better patients’ outcome and WALCE provides free logistical support to patients and a caregiver to access available clinical trial available outside the country of residence.

What can EPROPA do for me?

I am a
patient
I am a
doctor
In numbers

A growing community

Leveraging scientific networking, physicians joining to this project will experience the chance to discuss molecular data and treatment options.

Clinical trials

As of September 2020

Admitted patients

More information

Would you like to know more?

If you are interested in this specific project, please "CONTACT WALCE" to gain more information and directly ask opportunities to proceed or call at he WALCE Office: +39-0119026980

A structured network of institutions and companies

The aim of EPROPA is to create a European Research Network, involving Centers of Expertise in the treatment of lung cancer, different Pharma Companies and other entities, named the University of Turin and the International Association for the Study of Lung Cancer (IASLC) that have endorsed this program.

The Pharma Companies that support EPROPA are

       

AstraZeneca

Amgen

How doctors welcome EPROPA

“Three months after launching EPROPA program, 3 European countries are already active and are making use of this opportunity for their patients and 2 countries are waiting for Ethics Committee approval. Many patients have contacted us and, always involving the centers of reference, and we are pleased to have been of support in the diagnostic and therapeutic approach. In addition to having identified target molecular alterations in many of the samples examined, a few days ago the first patient also benefited from the second objective of EPROPA, accessing a clinical trial available in another center, on the basis of the analysis conducted”

Prof. Silvia Novello

President WALCE and Head of Thoracic Oncology Unit - San Luigi Hospital Orbassano/Turin – Italy

The voice of Partner Centers

Share your story on Facebook

#realstoriesrealpeople

Watch more

About WALCE

WALCE (Women Against Lung Cancer in Europe) is a non-profit Organisation based in Italy and networking at European level, founded in 2006 with the primary aim to increase women’s awareness about the significant incidence and mortality of lung cancer in female population and to support patients affected by this disease (and their families). WALCE currently provides accurate and updated information about lung cancer in terms of prevention, diagnosis and treatment, and it wants to promote communication strategies aim to aware public opinion and decision makers on damages of smoking. WALCE is mainly involved in: information and education dedicated to patients and their families, patient support programs and primary prevention.

Visit website